Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (31 quarters reported)
$120M in Q1 2014 → $14.1M now. Hover for any quarter.
As reported for the quarter ended September 30, 2021. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Lyra Therapeutics, Inc. | 71.3% | Unchanged | 1,100,852 | $10M |
| X4 Pharmaceuticals Inc. | 11.7% | Unchanged | 311,492 | $1.65M |
| Atyr Pharma Inc. | 8.4% | Unchanged | 130,572 | $1.19M |
| Dare Bioscience, Inc. | 3.9% | Unchanged | 326,240 | $545K |
| GB Genocea Biosciences, Inc. | 2.7% | Unchanged | 197,345 | $379K |
| Pulmatrix, Inc. | 2.0% | Unchanged | 359,441 | $288K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2021 · filed November 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Fate Therapeutics, Inc. | Exited | −569,889 | −$49.5M | — |
quarter ended June 30, 2021 · filed August 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SB Selecta Biosciences, Inc. | Exited | −2,773,479 | −$12.6M | — |
| Dare Bioscience, Inc. | Trimmed | −1 | −$2 | 1.0% |
quarter ended March 31, 2021 · filed May 12, 2021
No position changes this quarter.
quarter ended December 31, 2020 · filed February 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Fate Therapeutics, Inc. | Trimmed | −284,947 | −$25.9M | 67.6% |
| Neuronetics, Inc. | Exited | −732,583 | −$3.56M | — |
| Dare Bioscience, Inc. | Added | +1 | +$1 | 0.6% |
quarter ended September 30, 2020 · filed November 12, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Phreesia, Inc. | Exited | −2,214,092 | −$62.6M | — |
| Fate Therapeutics, Inc. | Trimmed | −284,947 | −$11.4M | 56.3% |
| GB Genocea Biosciences, Inc. | Trimmed | −48,733 | −$112K | 0.7% |
| Dare Bioscience, Inc. | Trimmed | −3 | −$3 | 0.5% |
| Pulmatrix, Inc. | Added | +2 | +$2 | 0.7% |
quarter ended June 30, 2020 · filed August 12, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Phreesia, Inc. | Trimmed | −1,000,000 | −$28.3M | 48.7% |
| Lyra Therapeutics, Inc. | New | +1,100,852 | +$12.5M | 9.7% |
| KP Kala Pharmaceuticals, Inc. | Exited | −565,289 | −$4.97M | — |
| Atyr Pharma Inc. | Added | +1 | +$4 | 0.5% |
quarter ended March 31, 2020 · filed May 14, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cardlytics, Inc. | Exited | −200,000 | −$12.6M | — |
quarter ended December 31, 2019 · filed February 12, 2020
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cardlytics, Inc. | Trimmed | −1,308,065 | −$82.2M | 9.1% |
| Phreesia, Inc. | Trimmed | −357,121 | −$9.51M | 62.3% |
| KP Kala Pharmaceuticals, Inc. | Trimmed | −631,743 | −$2.33M | 1.5% |
Loading...
